4//SEC Filing
Stanker James H 4
Accession 0000897069-24-000923
CIK 0001533743other
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 4:57 PM ET
Size
8.3 KB
Accession
0000897069-24-000923
Insider Transaction Report
Form 4
Stanker James H
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2024-01-01$2.79/sh−518$1,445→ 6,120 total - Exercise/Conversion
Restricted Stock Units
2024-01-01−1,675→ 24,037 totalExercise: $0.00→ Common Stock (1,675 underlying) - Exercise/Conversion
Common Stock
2024-01-01+1,675→ 6,638 total
Footnotes (2)
- [F1]Distribution of vested restricted shares.
- [F2]Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Documents
Issuer
Processa Pharmaceuticals, Inc.
CIK 0001533743
Entity typeother
Related Parties
1- filerCIK 0001681718
Filing Metadata
- Form type
- 4
- Filed
- Apr 11, 8:00 PM ET
- Accepted
- Apr 12, 4:57 PM ET
- Size
- 8.3 KB